The relative potency between high dose oral oxycodone and intravenous morphine: a case illustration
by
Zhukovsky DS, Walsh D, Doona M
Department of Medical Oncology,
Cleveland Clinic Foundation,
OH 44195, USA.
Arch Intern Med 2000 Mar 27;160(6):853-60

ABSTRACT

Oxycodone is an effective opioid analgesic for cancer pain. In the United States, it is available exclusively as an oral formulation, predominantly in fixed dose combination with acetaminophen or aspirin. The latter limits its use in cancer pain due to the potential toxicity of the nonopioid component. Oxycodone is now available as a single agent, controlled release formulation. The following case report of an opioid tolerant cancer patient taking repeated high doses of oral oxycodone supports the use of a 1:1 milligram conversion ratio for oral morphine and oral oxycodone. This patient's clinical course indicates that oral oxycodone can be used safely and to good effect at high dose, that the milligram relative potency ratio for oral oxycodone to parenteral morphine during repeated dosing is 3:1, and suggests that availability of multiple formulations of oxycodone may benefit cancer patients.

Pain
Morphine
Oxycodone
'Hillbilly heroin'?
Oxycodone: structure
Oxycodone: metabolism
Oxycodone for cancer pain
Tramadol versus oxycodone
Oxycodone versus morphine
OxyContin: politics and science
OxyContin: prescribing indications
Controlled-release oxycodone v morphine
Oxycodone: a pharmacological and clinical review

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family